Subinhibitory concentrations of LFF571 reduce toxin production by clostridium difficile

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1252-1257

  Sachdeva, Meena ^a   Leeds, Jennifer A ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM TOXIN; FIDAXOMICIN; LFF 571; METRONIDAZOLE; VANCOMYCIN; AMINOGLYCOSIDE; THIAZOLE DERIVATIVE;

AGAR DILUTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; CELL COUNT; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; LIMIT OF DETECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; SUPERNATANT; TOXIN ANALYSIS; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

AMINOGLYCOSIDES; CLOSTRIDIUM DIFFICILE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; THIAZOLES; VANCOMYCIN;

EID: 84921755570     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04436-14     Document Type: Article

References (24)

1. Rupnik M, Wilcox MH, Gerding DN. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7:526-536. http://dx.doi.org/10.1038/nrmicro2164.
2. Viswanathan VK, Mallozzi MJ, Vedantam G. 2010. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 1:234-242. http://dx.doi.org/10.4161 /gmic.1.4.12706.
3. Ananthakrishnan AN. 2011. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 8:17-26. http://dx.doi.org/10.1038/nrgastro.2010.190.
4. Gerding DN, Johnson S. 2011. Clostridium difficile infection in 2010: advances in pathogenesis, diagnosis and management of CDI. Nat Rev Gastroenterol Hepatol 8:67-68. http://dx.doi.org/10.1038/nrgastro.2010 .215.
5. Kuehne SA, Cartman ST, Minton NP. 2011. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes 2:252-255. http://dx.doi.org/10.4161/gmic.2.4.16109.
6. Davies AH, Roberts AK, Shone CC, Acharya KR. 2011. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem J 436:517-526. http://dx.doi.org/10.1042/BJ20110106.
7. st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
8. st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
9. st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
10. Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D. 2012. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother 56:4459-4462. http://dx.doi.org/10.1128 /AAC.06355-11.
11. st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
12. Leeds JA, Sachdeva M, Mullin S, Dzink-Fox J, LaMarche MJ. 2012. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother 56:4463-4465. http://dx.doi.org/10.1128/AAC.06354-11.
13. th ed. Approved standard M11-7. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Lyerly DM, Barroso LA, Wilkins TD, Depitre C, Corthier G. 1992. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun 60:4633-4639.
15. Moncrief JS, Zheng L, Neville LM, Lyerly DM. 2000. Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR. J Clin Microbiol 38:3072-3075.
16. Davies J, Spiegelman GB, Yim G. 2006. The world of subinhibitory antibiotic concentrations. Curr Opin Microbiol 9:445-453. http://dx.doi .org/10.1016/j.mib.2006.08.006.
17. Gerber M, Walch C, Loffler B, Tischendorf K, Reischl U, Ackermann G. 2008. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J Med Microbiol 57:776-783. http://dx.doi.org/10 .1099/jmm.0.47739-0.
18. Onderdonk AB, Lowe BR, Bartlett JG. 1979. Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation. Appl Environ Microbiol 38:637-641.
19. Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone KC, Young CL, Critchley IA, Janjic N. 2009. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 63:964-971. http://dx.doi.org/10.1093/jac/dkp042.
20. Mathur T, Kumar M, Barman TK, Kumar GR, Kalia V, Singhal S, Raj VS, Upadhyay DJ, Das B, Bhatnagar PK. 2011. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile . J Antimicrob Chemother 66:1087-1095. http://dx.doi.org/10.1093/jac/dkr033.
21. Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W. 2014. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58:892-900. http://dx.doi.org/10.1128/AAC.01830-13.
22. st Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
23. Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. 2013. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother 68:515-522. http://dx.doi.org/10.1093/jac/dks450.
24. Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, Praestgaard J, Leeds JA, Blais J, Pertel P. 22 December 2014. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. http://dx.doi.org/10.1128/AAC.04251-14.